Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
p24CE DNA vaccine + interleukin-12 DNA vaccine
- Development stage
- Unknown
- Lead developer
- University of California, San Francisco
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
p24CE DNA vaccine + interleukin-12 DNA vaccine is a combinatorial therapeutic DNA vaccine regimen developed by the University of California, San Francisco (UCSF) for the treatment of HIV-1 infection. The vaccine consists of a plasmid encoding conserved elements (CE) of the HIV-1 p24gag protein (p24CE) and a plasmid encoding interleukin-12 (IL-12) which acts as a genetic adjuvant. The p24CE immunogen is designed to focus the immune response on highly conserved regions of the HIV-1 capsid protein to avoid decoy epitopes and induce broad cellular immunity. The regimen is administered via intramuscular electroporation using the TriGrid Delivery System to enhance plasmid uptake and expression. It is being studied as part of a multi-component strategy to induce HIV remission in individuals on antiretroviral therapy (ART).
- Other names
- p24CE DNA + IL-12 DNAp24CE DNA vaccinep-24CE DNA vaccinep 24CE DNA vaccineIL-12 DNA vaccineIL12 DNA vaccineIL 12 DNA vaccinep24CE DNA vaccine + IL-12 DNA vaccine
02
Targets
p24 (HIV-1 capsid protein p24)IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on p24CE DNA vaccine + interleukin-12 DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on p24CE DNA vaccine + interleukin-12 DNA vaccine.